Research programme: toll-like receptor antagonist - Janus Biotherapeutics/RocheAlternative Names: JB6121; TLR inhibitor - Janus Biotherapeutics/Roche; Toll-like receptor inhibitor - Janus Biotherapeutics/Roche
Latest Information Update: 05 Jan 2016
At a glance
- Originator Janus Biotherapeutics
- Developer Janus Biotherapeutics; Roche
- Class Small molecules
- Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Systemic lupus erythematosus